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Abstract 
 
Biomarkers are regularly used in medicine to provide objective indicators of normal biological 
processes, pathogenic processes or pharmacological responses to therapeutic interventions, and have 
proved invaluable in expanding our understanding and treatment of medical diseases. In the field of 
psychiatry, assessment and treatment has, however, primarily relied on patient interviews and 
questionnaires for diagnostic and treatment purposes. Biomarkers in psychiatry present a promising 
addition to advance the diagnosis, treatment and prevention of psychiatric diseases. This review 
provides a summary on the potential of peripheral biomarkers in major depression with a specific 
emphasis on those related to inflammatory/immune and oxidative stress/antioxidant defences. The 
complexities associated with biomarker assessment are reviewed specifically around their collection, 
analysis and interpretation. Focus is placed on the potential of peripheral biomarkers to aid diagnosis, 
predict treatment response, enhance treatment-matching, and prevent the onset or relapse of major 
depression.  
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Abbreviations: 8-OHdG, 8-hydroxy-2-deoxyguanosine; 8-oxoGuo, 8-oxo-7,8-dihydroguanosine; BDNF, brain-derived neurotropic 
factor; BMI, body mass index; COX, cyclooxygenase; CRP, C-reactive protein; DSM, Diagnostic and Statistical Manual of Mental 
Disorders; ECT, electroconvulsive therapy; ESR, erythrocytes sedimentation rate; F2-isoPM, 2,3-dinor-5,6-dihydro-15-F2t-
isoprostane; GPx, glutathione peroxidase; GTP-CH1, GTP cyclohydrolase I; hs-CRP, high sensitivity CRP; IDO, indoleamine 2,3 
dioxygenase; IFN, interferon; IL, interleukin; IL-2R, interleukin-2 receptor; KYN, kynurenine; KYNA, kynurenic acid; MDA, 
malondialdehyde; RA, rheumatoid arthritis; RBC, red blood cell; RNA, ribonucleoside; SOD, superoxide dismutase; SSRI, 
serotonin reuptake inhibitor; TNF, tumour necrosis factor; TRP, tryptophan; TRYCATs, tryptophan catabolites along the IDO 
pathway.  
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Introduction 
Currently the diagnosis of major depression is carried out through a combination of patient 
interviews, checklists and self-report questionnaires. These generally rely on a list of symptoms 
derived from the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) and 
now more recently, its revised 5th edition, DSM-5. Unfortunately, there is debate about the value 
and objectivity of this symptom-based assessment process (Hilsenroth et al., 2004, Phillips et al., 
2012, Stein et al., 2010) particularly around limitations associated with the development of 
personalised treatment plans.  
Biomarkers are indicators of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention that can be measured and evaluated 
objectively (Biomarkers Definitions Working Group., 2001). They have the potential to overcome 
some of the issues associated with symptom-based assessments. In medical and pharmaceutical 
practice, biomarkers are regularly used to support the presence or absence of specific diseases 
(diagnostic biomarkers), predict optimal treatment options (treatment biomarkers), measure 
treatment progress (treatment-response biomarkers), and predict the onset of future disease 
(predictive biomarkers) (Boksa, 2013, Kluge et al., 2011, Schmidt et al., 2011). Unfortunately, 
progress in biomarker research on depression is hindered by the considerable heterogeneity 
associated with this disorder. While major depression comprises changes in sleep, appetite, 
weight, and psychomotor behaviour, these can involve both increases and decreases in symptoms. 
Complaints about the most debilitating depressive symptom or constellation of symptoms can also 
vary considerably across individuals. These include variations in the severity of fatigue, 
worthlessness, suicidal ideation, and effects on memory and concentration. Further complications 
include the high comorbidity between depression and other medical and psychiatric conditions 
(Voinov et al., 2013), and factors associated with unique differences across gender, age, lifestyle 
and other mediating or triggering factors. 
In this paper, many of the most commonly researched biomarkers in major depression are 
reviewed. Only peripheral biomarkers have been selected for review given their suitability and 
ease of collection in clinical practice. Furthermore, only biomarkers associated with inflammation/ 
immune response and oxidative stress/antioxidant defences have been selected for review as this 
is an area gaining momentum in depression research (Leonard and Maes, 2012, Maes et al., 2011b, 
Raison and Miller, 2011). 
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Common oxidative and inflammatory biomarkers measured in depression 
studies 
Several commonly-researched peripheral biomarkers in major depression are listed in Table 1, and 
pathways associated with their production are detailed in Figure 2. A brief description of each 
marker is provided, and they are categorised into inflammatory/immune response biomarkers and 
oxidative stress/antioxidant defence biomarkers. However, these markers are not mutually 
exclusive as they can greatly influence the production of other important biomarkers. 
 
<<insert Table 1 near here>> 
<<insert Figure 1 near here>> 
A summary of potential diagnostic biomarkers in depression 
Biomarkers may be used to assist clinical diagnosis. From a diagnostic perspective, their value 
is largely dependent on their ability to identify the presence (sensitivity) or absence (specificity) of 
disease. While these biomarkers are reviewed individually, it is likely that a combination of 
biomarkers will be required to increase sensitivity and specificity rates to levels required for 
diagnostic purposes (Schmidt et al., 2011). 
Inflammation and immune response biomarkers 
C-reactive protein (CRP) – findings from meta-analyses have confirmed that major depression is 
associated with increased CRP levels (Howren et al., 2009, Valkanova et al., 2013). In a recent meta-
analysis on longitudinal studies by Valkanova et al. (2013) it was also established that raised CRP 
levels were associated with an increased risk of subsequent depression. However, these findings 
are not uniform and in subgroup analyses, elevated CRP was associated with atypical depression 
(Hickman et al., 2013), somatic symptoms (Duivis et al., 2013), depressed men with an older age of 
depression onset (Vogelzangs et al., 2012), depressed men in general (Elovainio et al., 2009, Ford 
and Erlinger, 2004, Liukkonen et al., 2011), depressed patients with a greater history of childhood 
adversity (Miller and Cole, 2012), and cumulative depressive episodes (Copeland et al., 2012).  
High sensitivity CRP (hs-CRP) assays are a more sensitive measure of inflammation, having a 
range of measurement that extends below that typical of most conventional CRP assays. 
Investigations into the link between hs-CRP and depression are continuing, and on the whole 
provide further support for their relationship (Luukinen et al., 2010, Ma et al., 2010, Pasco et al., 
2010). 
Cytokines - along with research on CRP levels, cytokine profiles in patients with major 
depression are the most commonly measured immune biomarkers. In recent meta-analyses, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
disturbed cytokine profiles have been confirmed in patients with major depression. Significantly 
higher concentrations of tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were identified 
in a meta-analysis by Dowlati et al. (2010); and in a meta-analysis on community and clinical 
populations, elevated IL-1 and IL-6 were positively associated with depression (Howren et al., 
2009). Greater elevations in IL-6 were found in subgroups where depressive disorders were 
formally diagnosed, as opposed to a diagnosis made using standardised inventories. Populations 
obtained from inpatient and outpatient settings also had higher IL-6 levels compared to the 
general community (Hiles et al., 2012b). In a meta-analysis by Liu et al. (2012), elevated blood 
levels of soluble interleukin-2 receptor (sIL-2R), TNF-α and IL-6 in patients with depression were 
demonstrated, although effect sizes were significantly influenced by the composition of the blood 
sample. Specifically, differences in sIL-2R and IL-6 were significant both in plasma and serum, 
whereas TNF-α was significantly different from healthy controls only when it was measured via 
serum. Finally, in a systematic review and meta-analysis on longitudinal studies, IL-6 was 
associated with depressive symptoms, although after considering only correlations adjusted for 
confounding variables such as smoking, alcohol consumption, body-mass index, cholesterol level, 
physical activity, medication use or chronic illness, the relationship became statistically non-
significant (Valkanova et al., 2013).  
Neopterin – levels of plasma neopterin are increased in depressed patients (Celik et al., 2010, 
Maes et al., 2013, Maes et al., 1994, Maes et al., 2012b, Rybka et al., 2013) and particularly in 
patients suffering from melancholic symptoms (Maes et al., 2012a, Maes et al., 1994). Greater 
concentrations of neopterin were also reported in patients suffering from two or more episodes of 
depression compared to first-episode populations (Celik et al., 2010). Nevertheless, differences in 
concentrations of neopterin between depressed and healthy samples have not been identified in 
some studies (Hoekstra et al., 2001, O'Toole et al., 1998).  
Erythrocyte sedimentation rate (ESR) – higher ESR was identified in depressed patients 
compared to healthy volunteers (Chavda et al., 2011), and in depressed smokers compared to non-
depressed, never smokers (Vargas et al., 2013). ESR was also elevated in rheumatoid arthritis (RA) 
patients suffering from depression compared to non-depressed RA sufferers (Abdel-Nasser et al., 
1998).  
TRYCATs – The TRYCATs pathway is shown in Figure 2, and a summary of studies examining 
the relationship between depression and various TRYCAT analytes is provided in Table 2. In 
general, depression is associated with lowered tryptophan (TRP), increased indoleamine-2,3-
dioxygenase (IDO) activity and reduced levels of the neuroprotective TRYCAT, kynurenic acid 
(KYNA). However, this is not uniform (Gabbay et al., 2010, Maes et al., 2011a, Maes and Rief, 
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2012), indicating that increased TRYCAT activity may be related to specific subtypes of depression 
or depressive symptoms. IDO activity is increased in patients suffering from somatisation (Maes et 
al., 2011a, Maes and Rief, 2012), depressed patients with a history of suicide attempts (Sublette et 
al., 2011) and adolescents with depression and melancholic symptoms (Gabbay et al., 2010).  
 
<<insert Figure 2 near here>> 
 
<<insert Table 2 near here>> 
 
Oxidative stress and antioxidant defence biomarkers 
Malondialdehyde (MDA) –  MDA concentrations in depressed patients are by-and-large increased 
compared to healthy control groups (Bilici et al., 2001, Galecki et al., 2009a, Khanzode et al., 2003, 
Kotan et al., 2011, Ozcan et al., 2004, Sarandol et al., 2007). Elevated levels of MDA have also been 
identified in patients diagnosed with recurrent depressive disorder (Rybka et al., 2013), and 
concentrations are even greater in depressed patients with a history of recurrent episodes of 
depression compared to patients suffering from their first episode (Stefanescu and Ciobica, 2012). 
Elevated MDA levels have also been confirmed in depressed patients suffering from chronic heart 
failure (Michalakeas et al., 2011) and newly diagnosed gastric adenocarcinoma (Wei et al., 2009). 
8-hydroxy-2-deoxyguanosine (8-OHdG) –an association between depression and levels of 8-OHdG 
has been confirmed in several cross-sectional studies. Compared to a healthy comparison group, 
urinary (Maes et al., 2009) and serum (Forlenza and Miller, 2006) levels of 8-OHdG were greater in 
people suffering from major depression. Levels of 8-OHdG also correlated positively with the 
severity of depression (Forlenza and Miller, 2006, Jorgensen et al., 2013), and participants with 
recurrent episodes of depression had higher levels than those with single episodes (Forlenza and 
Miller, 2006). While no differences in urinary 8-OHdG were identified between depressed and 
healthy samples, its ribonucleoside (RNA) analogue, 8-oxo-7,8-dihydroguanosine (8-oxoGuo), was 
higher in depressed patients, particularly those suffering from severe depression (Jorgensen et al., 
2013). Increased 8-OHdG may be a characteristic of clinically-diagnosed depression, as no 
differences were found in community-based populations suffering from depressive symptoms 
(Iida et al., 2011, Yi et al., 2012).  
Isoprostanes – levels of isoprostanes are elevated in patients suffering from depression as 
demonstrated by higher urinary concentrations of 8-iso-PGF2α (Chung et al., 2013, Milaneschi et 
al., 2013), and a β-oxidation metabolite of 8-iso-PGF2α, 2,3-dinor-5,6-dihydro-15-F2t-isoprostane 
(F2-isoPM). It is important to note that Milaneschi et al. (2013) found this association in men but 
not women. Elevated serum (Yager et al., 2010) and plasma (Dimopoulos et al., 2008) 8-iso-PGF2α, 
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concentrations were also found in depressed populations compared to a healthy comparison 
group. 
Superoxide dismutase (SOD) – disturbances in SOD activity are generally found in depressed 
populations. However, findings are inconsistent in the direction of this disturbance. For example, 
decreased red blood cell (RBC) SOD activity was reported in patients diagnosed with recurrent 
depressive disorder (Rybka et al., 2013), lowered serum SOD levels in patients with major 
depression (Herken et al., 2007, Stefanescu and Ciobica, 2012), and even greater reductions in 
serum SOD in patients with recurrent depression, compared to a first episode group (Stefanescu 
and Ciobica, 2012). However, in other studies increased RBC SOD in depressed patients were 
found (Bilici et al., 2001, Galecki et al., 2009a, Kodydkova et al., 2009, Kotan et al., 2011, Sarandol et 
al., 2007), and serum SOD was positively associated with increasing severity of depression 
(Khanzode et al., 2003). Reasons for these inconsistent findings are not clear, although may be 
related to variable collection protocols, analysis methods and whether RBC or serum was analysed 
(e.g., RBC levels were elevated in four out of five studies reviewed, while serum levels were lower 
in two out of three studies reviewed). Differences in the characteristics of depressed populations 
sampled may also be important as severity (Khanzode et al., 2003) and length of depression 
(Stefanescu and Ciobica, 2012) are important factors influencing SOD activity. 
Glutathione –As shown in Table 3, conclusions regarding glutathione activity are difficult as 
findings have been inconsistent and often dependent on the glutathione measure used and type of 
specimen evaluated. Levels of RBC glutathione peroxidase (GPx) have been most commonly 
evaluated in depressed populations with decreases (Kodydkova et al., 2009, Rybka et al., 2013), 
increases (Bilici et al., 2001), and no differences (Galecki et al., 2009a) found between depressed 
and healthy control groups.  
 
<<insert Table 3 near here>> 
Biomarkers associated with the treatment of depression 
The potential of biomarkers as a measure of treatment response 
Measures of treatment progress over time are provided by treatment-response biomarkers. 
Currently, assessment of treatment progress in major depression is undertaken in clinical practice 
through clinical interviews, and to a lesser extent questionnaires and inventories. With validation 
of treatment-response biomarkers, further data about treatment efficacy may also be obtained by 
monitoring changes in biomarker levels over time.  
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CRP – in a meta-analysis of eight studies investigating the effects of antidepressant treatment on 
CRP levels it was concluded that antidepressant medication (particularly selective serotonin 
reuptake inhibitors, SSRIs) marginally lowered levels of CRP (Hiles et al., 2012a). However, in a 
meta-regression in this review, no significant association between baseline CRP and change in 
depressive symptoms was identified. Moreover, a trend was noted where higher baseline CRP was 
associated with larger decreases in depressive symptoms.  
Cytokines – in a meta-analysis by Hannestad et al. (2011), antidepressant treatment was found to 
lower levels of IL-1β and possibly IL-6, but had no effect on TNF-α. In a further analysis of 
antidepressant classes, SSRIs lowered levels of IL-6 and TNFα (Hannestad et al., 2011). In a 
separate meta-analysis, it was confirmed that antidepressants lowered levels of IL-6 and non-
significantly decreased levels of IL-10. A pattern was also identified where higher baseline IL-6 
was associated with larger decreases in depressive symptoms (Hiles et al., 2012a).  
Electroconvulsive therapy (ECT) also influences cytokine profiles in depressed patients. ECT 
increased IL-1β and IL-6 at 3- and 6-hour time points after treatment (Lehtimaki et al., 2008). 
Hestad et al. (2003) demonstrated that the clinical improvement during repeated ECT was 
accompanied by a gradual and significant decline in TNF-α, reaching levels comparable with those 
in healthy controls at the end of the study. Such a decline was not seen in depressed patients not 
receiving ECT, who instead showed elevated TNF-α levels throughout the study period. 
Neopterin – a course of treatment with ECT significantly elevated neopterin levels in depressed 
responders but these levels did not change in non-responders (Hoekstra et al., 2001). Anderson et 
al. (1992) found that a positive therapeutic response was associated with a reduced 
neopterin:biopterin ratio in patients with psychotic depression treated with ECT. 
Malondialdehyde (MDA) –changes in MDA levels following treatment with antidepressant 
medication are largely associated with reduced concentrations and a return to normal levels in 
patients recovering from major depression. After three months of treatment with SSRIs, MDA was 
reduced to levels similar to a healthy comparison group (Bilici et al., 2001, Khanzode et al., 2003). 
Reductions in MDA were also observed in first-episode depressive patients who achieved 
remission following three months of treatment with fluoxetine (Galecki et al., 2009a). MDA also 
decreased significantly following 24 weeks of antidepressant treatment (Kotan et al., 2011); 
however, no such change was observed after a shorter treatment period of 6 weeks (Sarandol et al., 
2007). 
8-hydroxy-2-deoxyguanosine (8-OHdG) – a single study was identified examining changes in 8-
OHdG following psychiatric treatment. Jorgensen et al. (2013) found no change in 8-OHdG levels 
following ECT although its RNA analogue, 8-oxoGuo, increased significantly.  
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Isoprostanes –the effect of antidepressant treatment on isoprostane levels has been investigated 
in one study. Excretion of F2 isoprostanes increased significantly following 8 weeks of treatment 
with bupropion or sertraline in patients with major depression. The researchers also found that 
increases in F2 isoprostane were associated with improvement in depression severity  (Chung et 
al., 2013). 
Superoxide dismutase – research on the effect of antidepressant medication on SOD activity has 
been inconsistent. RBC SOD activity was lowered following treatment with different classes of 
antidepressants after 24 weeks, although no change was noted after 6 or 12 weeks (Kotan et al., 
2011). Serum SOD activity was lowered following 8 weeks of SSRI administration (Khanzode et al., 
2003), and RBC SOD was reduced after 3 months of treatment with several antidepressant classes 
(Bilici et al., 2001). In contrast to these findings, no significant change in RBC SOD was observed in 
patients after 3 months of treatment with fluoxetine (Galecki et al., 2009a, Galecki et al., 2009b), or 
in patients following 6 weeks of treatment with several antidepressant classes (Bilici et al., 2001). 
Further disparity in findings is demonstrated by Herken et al., (2007) where 8 weeks of SSRI 
treatment was associated with increased serum SOD levels. Unique to this study was the 
observation that baseline SOD levels were lowered (rather than elevated) in the depressed 
population compared to the control group.  
In sum, the effect of antidepressant medication on SOD activity is not clear. These inconsistent 
findings may be attributed to the varying antioxidant effects of different antidepressant classes, or 
to differences in the depressed populations studied, as SOD activity is influenced by the number of 
depressive episodes (Stefanescu and Ciobica, 2012) and severity of depression (Khanzode et al., 
2003). Blood samples used in the studies (e.g., serum or RBC) and the length of antidepressant 
treatment may also be important factors influencing findings. 
Glutathione activity - No change in GPx was observed after three months of treatment with 
fluoxetine (Galecki et al., 2009a) or 24 weeks of antidepressant treatment (Kotan et al., 2011). 
Galecki et al. (2009b) found that the addition of acetylsalicylic acid to fluoxetine treatment 
provided no additional benefit to treatment efficacy, although it was able to lower GPx activity 
after 3 months. Plasma glutathione reductase and glutathione peroxidase decreased after 3 months 
of treatment with SSRIs (Bilici et al., 2001). 
TRYCATs - Little or no change was observed in the concentrations of any of the TRYCATs 
following treatment with fluoxetine, fluoxetine plus the thyroid hormone triiodothyronine (T3), or 
counselling (Mackay et al., 2009).  Despite this, in a correlation analysis at weeks 6 and 18, highly 
significant relationships between several of the TRYCATs and psychiatric inventory scores were 
revealed. In patients treated with fluoxetine or fluoxetine and T3, positive correlations were 
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observed between psychiatric rating scores and concentrations of tryptophan and some TRYCATs, 
such as kynurenic acid and 3-hydroxyanthranilic acid. That is, increased levels of some TRYCATs 
were associated with increased psychiatric severity.  Myint et al. (2007) found no changes in the 
TRYCATs, kynurenine, kynurenic acid and tryptophan, and related ratios after 6 weeks of 
antidepressant treatment. The neuroprotective ratio of patients with their first episode of 
depression increased significantly after treatment, but this did not correlate with changes in 
depression severity. 
Overall, the studies reviewed above suggest that treatments for depression (particularly 
antidepressant medication and ECT) influence oxidative stress and inflammatory markers. 
Unfortunately, investigations into the significance of such findings are still in their infancy. In the 
majority of studies the relationship between biomarker variations and changes in depressive 
symptoms has not been examined, making conclusions about the value of biomarker evaluations 
as a measure of treatment success difficult. Where studies have investigated this relationship, 
findings have been inconsistent. Moreover, the mechanisms underlying biomarker variation are 
unknown. While the treatments per se may improve inflammatory and oxidative stress pathways, 
it is also possible that improved mood resulting from successful treatment could lead to cognitive, 
behavioural and lifestyle changes (e.g., increased exercise, improved diet, positive outlook, 
improved sleep) that may be responsible for the changes observed in biomarkers. Further research 
in this area is required.  
The potential of biomarkers for enhancing treatment matching  
The potential of inflammatory and oxidative stress biomarkers to facilitate treatment matching 
and, in turn, enhance treatment efficacy has been examined in only a few studies. From a 
theoretical standpoint, assessment of pre-treatment biomarkers has the potential to enhance 
clinical decision-making by enabling clinicians to choose the most appropriate treatment for a 
specific individual or group of individuals. Monitoring changes in biomarkers following treatment 
may also provide an indication of the likelihood of treatment success.   
In a study by Raison et al. (2013), infliximab, a TNF antagonist, was administered (via infusion) 
to patients with major depression. When the depressed group was examined as a whole, 
infliximab was no more effective than placebo. However, in patients with a baseline hs-CRP 
greater than 5 mg/L, a significantly greater treatment response was observed in infliximab-treated 
patients compared to placebo. Additionally, Change et al. (2012) found that baseline CRP levels 
correlated significantly with the response to antidepressant treatment at week 2. However, in 
patients with comorbid coronary heart disease and depression treated with antidepressants, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
baseline levels of hs-CRP were not associated with 10-week post-treatment depression scores (Bot 
et al., 2011). 
The potential of biomarkers to predict the onset of depression 
Preventative-based efforts hold significant promise in reducing the prevalence of depression 
and other psychiatric disorders in the general community. Currently several psychological, 
lifestyle, social and physical factors are known to be associated with an increased risk of 
developing major depression or relapsing after a period of remission. Measurement of biomarkers 
presents an additional option for risk factor identification, further enabling decision making 
around early identification, treatment and relapse prevention. 
Research into the predictive potential of inflammatory and oxidative stress markers is still in its 
early stages. However, in a prospective analysis, increasing CRP levels were associated with 
increasing risk for hospitalisation with depression (Wium-Andersen et al., 2013). Greater CRP 
levels were also identified as an independent risk marker for de novo depression in women (Pasco 
et al., 2010). Liukkonen et al. (2006) also found a four-fold increase in the likelihood of recurrent 
depression in men with a hs-CRP level greater than 3 mg/L, although no such association was 
identified in women. In a meta-analysis of longitudinal studies, raised CRP, and to a lesser extent 
IL-6, was associated with an increased risk of subsequent depressive symptoms (Valkanova et al., 
2013). In a study on people undergoing IFN-α treatment for hepatitis C, kynurenic acid levels were 
positively associated with an increased risk of the development of depression (Wichers et al., 
2005).  
Complexities in biomarker identification 
The clinical utility of biomarkers in psychiatry is still in its infancy. Although biomarker 
measurement has the potential to be an exciting addition to psychiatric assessment, it is associated 
with numerous complexities. As demonstrated in this review, a number of inflammatory and 
oxidative stress biomarkers are associated with depression. However, none of these has sufficient 
sensitivity and specificity to be used in isolation. This signifies that further research is required to 
identify alternative, more suitable single or collective biomarkers. However, results have also been 
hampered by numerous inconsistencies and challenges across studies. 
Inconsistencies in specimen collection are a serious drawback in research. Typically, blood, 
urine and saliva samples are collected in research studies. Within blood collections, plasma, 
serum, red blood cells, and whole blood are additional options for biomarker measurement. A 
major drawback associated with the studies reviewed above relates to variation in the specimens 
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utilised to make comparisons. This may at least partly account for the inconsistent findings across 
studies. Further research is required to determine the most appropriate and accurate specimen to 
be utilised in research and clinical practice.  
A related problem refers to inconsistency in collection, storage and measurement protocols. 
While the majority of studies utilised morning, fasting collections, this was not always the case. 
Protocols used to measure biomarkers also often lacked consistency as did storage conditions 
following collection. Further research is required to determine the most accurate collection, storage 
and measurement protocols. Such protocols also need to be cost-effective and easily applied in 
clinical settings.  
A greater understanding of patient variables such as age, sex, medication use, menstrual cycle 
and status, time of day, smoking status and BMI are also crucial factors to consider in protocol 
development (Codoner-Franch et al., 2012, Hrboticky et al., 1989, Rosello-Lleti et al., 2012, 
Theofylaktopoulou et al., 2013). Although depression is associated with several inflammatory and 
oxidative stress biomarkers, confounding variables need to be accounted for. For example, despite 
CRP being commonly used as a marker of inflammation and cardiovascular disease, levels may be 
influenced by time of day (Koc et al., 2010, Rudnicka et al., 2007), gender (Khera et al., 2005, 
Lakoski et al., 2006), age (Shanahan et al., 2013, Woloshin and Schwartz, 2005), menstrual cycle 
(Gaskins et al., 2012, Wander et al., 2008), and BMI (Choi et al., 2013). These factors will impact on 
the reliability of conclusions made and require consideration in hypothesis generation. Some of 
these problems may be overcome by establishing subgroup normative data (e.g., based on age and 
gender) for the varying markers discussed. 
Inconsistencies in patient populations used in research also present another serious problem. 
Major depression is a heterogeneous disorder, thereby making generalised conclusions difficult. 
There is a need for investigation into biomarkers associated with specific depression subtypes, 
categories or even specific symptoms. Atypical, melancholic, suicidal, and somatic-dominant are 
examples of some ‘depression subtypes’ that have revealed differing biomarker profiles. The 
specificity and sensitivity of biomarkers may increase following examination of well-defined 
groups. 
The effect of treating depression on biomarkers has primarily focused on antidepressant 
medication and ECT. Research into other treatments such as psychological therapies and lifestyle 
interventions (e.g., sleep, diet and exercise) is lacking. The influence of more targeted anti-
inflammatory treatments and antioxidant therapies on depressive symptoms and biomarker levels 
are also required. It seems logical that if oxidative stress or inflammation is dysregulated in an 
individual or a population group, then treatments targeting this dysregulation should be utilised. 
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Preliminary research into anti-inflammatory medication has begun with some positive initial 
findings (Muller et al., 2011). However, as recently determined by Raison et al. (2013), treatment 
with infliximab, a TNF antagonist, was effective only for individuals with high levels of CRP. 
Other potential treatment candidates include COX-2 inhibitors (Muller et al., 2011), immune-
modulating and antioxidant herbs and spices such as curcumin (Lopresti et al., 2012) and green tea 
(Cabrera et al., 2006, Rietveld and Wiseman, 2003), and the large array of antioxidant nutrients 
such as coenzyme Q10, zinc, vitamin C, vitamin E and n-acetylcysteine (Ng et al., 2008, Zhang and 
Yao, 2013). Further investigation into the effects of specific antidepressant medications on 
inflammatory and oxidative stress markers may also facilitate better treatment matching.  
Finally, while a limited selection of more commonly assessed biomarkers in depression 
research, specifically targeting inflammation and oxidative stress, have been covered in this 
review, there remains an array of other potential options. These include measurements of amino 
acid levels, which are the precursors to neurotransmitters; markers of neurogenesis such as brain-
derived neurotrophic factor; neurotransmitter metabolites such as 5-hydroxyindoleacetate, 
vanilmandelate and homovanillate (measures of serotonin, noradrenaline and dopamine 
respectively); growth factors such as insulin-like growth factor-1 and vascular endothelial growth 
factor; endocrine markers such as cortisol; measures of individual antioxidant levels such as zinc, 
coenzyme Q10, selenium and collective antioxidant measures such as total antioxidant capacity; 
markers of nitrosative stress such as conjugated nitric-oxide (NO) adducts, - NO-tryptophan, NO-
tyrosine, NO-arginine, and NO-cysteinyl; and genetic polymorphisms associated with serotonin 
and dopamine transporters and receptors. 
Before biomarkers for depression can introduced into clinical practice, substantially greater 
research is required. Major depression is a common mental disorder with current treatment 
remission rates reaching only 20 to 40% (Warden et al., 2007). The addition of biomarkers has the 
potential to advance a more personalised treatment approach and enhance treatment efficacy. 
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Figure 1. Pathways associated with oxidative stress and inflammatory biomarkers in major depression. Elevated 
pro-inflammatory cytokines (e.g, IL-6, TNF-α, and IFN-γ) upregulate the production of enzymes indoleamine 2,3 
dioxygenase (IDO) and GTP cyclohydrolase I (GTP-CH1), leading to increased production of TRYCATs and 
neopterin, respectively. ESR and CRP are also markers of inflammation. Oxidative stress is influenced by 
antioxidant defence systems including the antioxidant enzymes SOD and GPx. Elevated oxidative stress may lead 
to a greater production of OHdG, MDA and isoprostanes. A bidirectional relationship exists between inflammation 
and oxidative stress, up- or down-regulating each other’s production. 
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Figure 2. TRYCATs pathway. The TRYCATs pathway starts with the degradation of tryptophan by the enzyme, 
indoleamine 2,3-dioxygenase (IDO) which is upregulated by pro-inflammatory cytokines (e.g. IFN-γ, TNF-α, IL-, 
IL-6). These TRYCATS have neuroprotective and neurotoxic effects on the CNS and influence monoaminergic 
transmission. 
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Table 1. Common peripheral biomarkers measured in studies on major depression 
 
Inflammation and immune response peripheral biomarkers 
C-reactive protein 
(CRP) 
An acute-phase protein found in the blood that rises in response to inflammation. 
Cytokines Immuno-modulating proteins, peptides, or glycoproteins (e.g., interleukins and 
interferons) secreted by specific cells of the immune system, which carry signals 
locally between cells, and have an effect on target cells. Cytokines are generally 
classified by their ability to promote or inhibit inflammatory responses and the 
type of T-lymphocytes with which they are associated (termed Th1, Th2, and 
Th17). 
Neopterin Released by macrophages and considered a marker of cell-mediated inflammation 
activation. 
Erythrocyte 
sedimentation rate 
(ESR) 
A non-specific index of inflammation which measures the rate at which red blood 
cells sediment in a period of one hour.  
TRYCATs 
(tryptophan 
catabolites along the 
IDO pathway) 
Production of TRYCATs such as kynurenine, kynurenic acid, xanthurenic acid, and 
quinolinic acid, may be increased following immune activation. An immune 
response induces indoleamine-(2,3)-dioxygenase (IDO), an enzyme which degrades 
tryptophan down the TRYCAT pathway, summarised in Figure 1. 
Oxidative stress and antioxidant defence peripheral biomarkers 
Malondialdehyde 
(MDA) 
Product of chemical damage caused by oxygen free radicals to the lipid component 
of cell membranes. 
8-hydroxy-2-
deoxyguanosine  
(8-OHdG) 
A repair product of the oxidation of guanine in DNA, can be used to estimate the 
rate of oxidative DNA damage.  
Isoprostanes Prostaglandin-like compounds produced by non-enzymatic peroxidation of 
arachidonic acid.  
Superoxide 
dismutases (SOD) 
Important antioxidant defence in nearly all cells exposed to oxygen. Enzymes that 
catalyse the dismutation of superoxide into oxygen and hydrogen peroxide.  
Glutathione 
peroxidase (GPx) 
Enzyme that catalyses the reduction of hydroxyperoxides by glutathione. Main 
function is to protect against the damaging effect of endogenously formed 
hydroxyperoxides. 
Glutathione 
reductase 
Important cellular antioxidant enzyme that reduces glutathione disulfide (GSSG) to 
the sulfhydryl form glutathione. 
Reduced glutathione Measure of glutathione status. 
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Table 2. Summary of TRYCAT depression studies. Elevated KYN and KYN/TRP indicates greater 
IDO activity. Elevated KYNA and KYNA/KYN ratio indicates greater neuroprotection. 
 
Population 
Sample 
used 
Tryptophan 
IDO activity Neuroprotection  
KYN KYN/TRP 
Ratio 
KYNA KYNA/KYN 
ratio 
Reference 
Healthy 
pregnant 
women  
Morning 
plasma 
after 
overnight 
fast 
No 
correlation 
with 
depression or 
anxiety 
postpartum 
Positively 
correlated 
with 
depression 
and anxiety 
postpartum 
Positively 
correlated 
with 
depression 
and anxiety 
postpartum 
  Maes et al. 
(2002) 
Depressed 
patients; 
healthy 
controls 
Morning 
plasma 
after 
overnight 
fast 
No difference 
between 
depressed 
and controls 
No 
difference 
 in 
depressed 
than 
controls 
 in 
depressed 
than 
controls 
 in 
depressed 
than 
controls 
Myint et al. 
(2007) 
 
Women 
high risk for 
postpartum 
depression 
Serum; 
time of 
collection 
not 
specified 
Negatively 
correlated 
with total 
depression 
score in the 
prepartum 
period, but 
not in other 
time periods. 
Not 
correlated 
with 
depressive 
symptoms 
over time 
Not 
correlated 
with 
depressive 
symptoms 
over time 
  Scrandis et 
al. (2008) 
Patients 
with 
coronary 
artery 
disease 
Morning 
plasma 
after 
overnight 
fast 
No 
correlation 
with 
depression 
scores 
 Positively 
correlated 
with 
depression 
scores 
  Swardfager 
et al. (2009) 
Depressed 
adolescents 
with 
melancholic 
features; 
non-
melancholic 
depressed 
adolescents; 
healthy 
controls 
Morning 
plasma 
after 
overnight 
fast 
 in 
melancholic 
than controls 
and non-
melancholic. 
No 
difference 
between all 
groups 
 in 
melancholic 
than 
controls 
and non-
melancholic 
  Gabbay et 
al. (2010) 
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Population 
Sample 
used 
Tryptophan 
IDO activity Neuroprotection  
KYN KYN/TRP 
Ratio 
KYNA KYNA/KYN 
ratio 
Reference 
Normal 
controls 
(NC); 
patients 
with 
somatization 
(SOM); 
patients 
with 
depression 
(DEP); 
patients 
with 
comorbid 
somatization 
and 
depression 
(SOM+DEP) 
Morning 
plasma 
after 
overnight 
fast 
 SOM 
compared to 
SOM+MDD, 
MDD and 
HC; No 
difference 
between 
SOM+MDD 
and MDD;  
SOM+MDD 
and 
MDD than 
HC. 
 SOM and 
SOM+DEP 
than NC. 
 SOM 
than 
SOM+MDD 
and NC; no 
difference 
between 
SOM and 
MDD or 
MDD 
versus NC. 
 SOM 
and 
SOM+MDD 
than MDD 
and NC;  
MDD to 
NC. 
 SOM 
than MDD 
and NC;  
SOM+MDD 
than MDD 
and NC; no 
difference 
between 
MDD and 
NC. 
Maes et al. 
(2011a) 
Depressed 
patients; 
healthy 
volunteers 
Plasma; 
Time of 
collection 
not 
specified 
 in suicide 
attempters 
than non-
attempters; 
No difference 
between 
depressed 
and controls 
No 
difference 
between 
depressed 
and controls; 
 in suicide 
attempters 
than non-
attempters 
 in 
depressed 
than 
controls 
  Sublette et 
al. (2011) 
Depressed 
patients; 
healthy 
controls 
Plasma 
collected 
in early 
afternoon 
 in 
depressed 
than controls 
No 
difference 
between 
groups 
 in 
depressed 
than 
controls 
No 
difference 
between 
groups 
 in 
depressed 
than 
controls 
Hughes et 
al. (2012) 
Normal 
controls 
(NC); 
patients 
with 
somatization 
(SOM); 
patients 
with 
depression 
(DEP); 
patients 
with 
comorbid 
somatization 
and 
depression 
(SOM+DEP) 
Morning 
plasma 
after 
overnight 
fast 
 SOM than 
all other 
groups; no 
difference in 
SOM+DEP 
and DEP. No 
difference 
between 
SOM+DEP 
and DEP;   
in SOM+DEP 
and DEP 
than HC 
  SOM 
than in NC. 
  SOM and 
SOM+DEP 
than in DEP 
and NC. 
Maes and 
Rief (2012) 
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Population 
Sample 
used 
Tryptophan 
IDO activity Neuroprotection  
KYN KYN/TRP 
Ratio 
KYNA KYNA/KYN 
ratio 
Reference 
Depressed 
inpatients; 
healthy 
controls 
Morning 
serum 
after 
overnight 
fast 
 depressed 
than controls 
 in 
depressed 
than 
controls 
 in 
depressed 
than 
controls 
  Myint et al 
(2013) 
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Table 3. Summary of studies investigating glutathione status in major depression. 
 
Glutathione measure Direction of change 
compared to controls 
Study 
Glutathione peroxidase  RBC Rybka et al., (2013) 
  RBC Kodydkova et al., (2009) 
  RBC Bilici et al., (2001) 
 = RBC Galecki et al., (2009a) 
  whole blood Maes et al., (2011c) 
 = whole blood Kotan et al., (2011) 
 = plasma Bilici et al., (2001) 
  serum 
in recurrent depression 
Stefanescu & Ciobica (2012) 
Glutathione reductase = RBC Rybka et al. (2013) 
 = RBC Bilici et al., (2001) 
  plasma Bilici et al., (2001) 
Reduced glutathione  whole blood Rybka et al. (2013) 
() increased () decreased or (=) no change compared to controls 
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Highlights 
 
 Inflammation and oxidative stress are associated with major depression 
 Peripheral biomarkers may aid diagnosis and predict future onset of depression 
 Peripheral biomarkers may enhance treatment-matching in depression 
 
